查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1139889

移植物抗宿主病市場：按產品類型，按治療類型，按最終用戶：2021-2031 年全球機會分析和行業預測

Graft Versus Host Disease Market By Product Type, By Treatment Type, By End Use : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 230 Pages | 商品交期: 2-3個工作天內

價格

2021 年全球移植物抗宿主病市場價值為 29.686 億美元，到 2031 年將達到 103.753 億美元，預計 2022 年至 2031 年的複合年增長率為 13.5%。

移植物抗宿主病 (GVHD) 是異基因移植（骨髓移植）後可能發生的疾病。在GVHD中，捐贈的骨髓和外周血幹細胞將接受者的身體視為異物，捐贈的細胞和骨髓會攻擊身體。 GVHD 有兩種形式：急性移植物抗宿主病 (aGVHD) 和慢性移植物抗宿主病 (cGVHD)。

aGVHD 和 cGVHD 的病理生理學仍未完全了解。即損傷腸黏膜和肝臟等宿主組織的調理療法，激活供體T細胞對抗宿主抗原並隨後擴增克隆T細胞，白細胞介素-1（IL-1）和腫瘤壞死因子（TNFα）釋放炎症細胞毒性等細胞因子會導致進一步的宿主組織損傷。幾種機制有助於 cGVHD 的發展，包括供體來源的同種異體反應性 T 細胞、自身反應性 T 細胞和產生針對宿主的抗體的 B 細胞的持續存在，以及導致終末器官纖維化的慢性炎症機制。涉及。

儘管在移植後免疫抑制治療方面進行了數十年的研究和改進，移植物抗宿主病 (GVHD) 仍然是異基因造血幹細胞移植 (HSCT) 受者發病率和死亡率的重要原因。

COVID-19 大流行正在影響世界各地的各種企業。移植物抗宿主病市場也產生了重大影響。為了阻止 COVID-19 的傳播，世界各國政府都實施了嚴格的規定，包括關閉邊境、限制和嚴格的社會隔離措施。這些措施對全球經濟產生了重大影響，影響了各個行業。製藥和生物技術公司正在與世界各地的政府合作應對 COVID-19 疫情，從支持疫苗開發到規劃藥物供應鏈挑戰。目前大約有 115 種候選疫苗和 155 種分子在研發中。

COVID-19 的影響 COVID-19 大流行已經深刻改變了美國和全球的腎移植格局。大流行不僅對受者同種異體移植物和腎移植後的患者生存產生了不利影響，而且還影響了移植物的轉診和上市、器官捐贈率、器官採購和運送、等待名單死亡率以及移植醫學的其他方面。

隨著腎移植率的下降，器官獲取率也在下降。英國報告稱，轉診至 OPO 的器官減少了 39%。法國報告說，與往年相比，全死亡器官採購減少了 16%。其中一些下降是由於缺乏測試能力和 COVID-19 測試結果延遲、手術室的可用性有限、強制避免不必要的臨床活動以保護人員和防護設備以及該組織面臨的採購挑戰。

因此，由於移植手術數量的減少，COVID-19 對移植物抗宿主病市場的總體影響仍然是負面的。植入手術需要常規使用可重複使用的器械，並與患者密切接觸。這增加了疾病傳播的風險。

移植物抗宿主病的增加主要是由於同種異體移植的增加。疾病診斷率的提高和移植物抗宿主病治療產品的增加也是推動市場增長的因素。

根據器官採購和移植網絡的初步數據，2020 年，美國已故捐獻者的器官捐贈創下歷史新高。共有 12,587 人捐贈了一個或多個器官來拯救或改善他人的生命，比 2019 年增加了 6%。

此外，死者捐贈的大部分增加是由於捐贈者的表現低於傳統醫療標準。已故捐贈者最常見的年齡組是 50-64 歲。與 2019 年相比，該類別的 3,726 名捐助者增加了 7.9%。與腦死亡相比，死於心肺功能不全的人的捐贈顯著增加，有 3223 名心肺死亡後捐贈者（DCD 捐贈者），比 2019 年的總數增加了 18.6%。

根據器官捐獻統計，全國等待器官移植的人數為105988人，而每天等待器官移植的人死亡17人，預計2021年將進行40000例移植手術。完成了。

術後並發症，如計算生物學無法檢測到的過敏反應、不利的政府情景、設備的高初始和維護成本、缺乏標準化、缺乏熟練勞動力等，將在預測期內影響市場。預計成為增長的主要障礙。

移植物抗宿主病市場根據產品、診斷、類型、最終用途和地區進行細分。按產品劃分，它分為皮質類固醇、單克隆抗體、免疫抑製劑等。按類型分為急性期和慢性期。最終用途分為醫院藥房、零售藥房和在線藥房。

內容

第一章介紹

第 2 章執行摘要

第 3 章市場概覽

  • 市場定義和範圍
  • 主要發現
    • 主要投資領域
  • 波特五力分析
  • 主要公司的定位
  • 市場動態
    • 驅動程序
    • 約束因素
    • 機會
  • COVID-19 影響分析

第 4 章移植物抗宿主病市場：按產品類型分類

  • 概覽
    • 市場規模和預測
  • 皮質類固醇
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 單克隆抗體
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 免疫抑製劑
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 其他
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 5 章移植物抗宿主病市場：按治療類型分類

  • 概覽
    • 市場規模和預測
  • 急性 GVHD
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 慢性 GVHD
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 6 章移植物抗宿主病市場：按最終用戶分類

  • 概覽
    • 市場規模和預測
  • 醫院藥房
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 零售藥房
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類
  • 在線藥店
    • 主要市場趨勢、增長因素和機遇
    • 市場規模和預測：按地區
    • 市場分析：按國家/地區分類

第 7 章移植物抗宿主病市場：按地區劃分

  • 概覽
    • 市場規模和預測
  • 北美
    • 主要趨勢和機遇
    • 北美市場規模和預測：按產品類型
    • 北美市場規模和預測：按治療類型
    • 北美市場規模和預測：按最終用途分類
    • 北美市場規模和預測：按國家/地區分類
      • 美國
      • 加拿大
      • 墨西哥
  • 歐洲
    • 主要趨勢和機遇
    • 歐洲市場規模和預測：按產品類型
    • 歐洲市場規模和預測：按治療類型
    • 歐洲市場規模和預測：按最終用途分類
    • 歐洲市場規模和預測：按國家/地區分類
      • 德國
      • 法國
      • 英國
      • 意大利
      • 西班牙
      • 其他歐洲地區
  • 亞太地區
    • 主要趨勢和機遇
    • 按產品類型劃分的亞太市場規模和預測
    • 按治療類型劃分的亞太地區市場規模和預測
    • 亞太市場規模和預測：按最終用途分類
    • 亞太地區的市場規模和預測：按國家/地區分類
      • 日本
      • 中國
      • 澳大利亞
      • 印度
      • 韓國
      • 其他亞太地區
  • LAMEA
    • 主要趨勢和機遇
    • LAMEA 市場規模和預測：按產品類型
    • LAMEA 市場規模和預測：按治療類型
    • LAMEA 市場規模和預測：按最終用途分類
    • LAMEA 市場規模和預測：按國家/地區分類
      • 巴西
      • 土耳其
      • 南非
      • LAMEA 的其餘部分

第八章企業情況

  • 簡介
  • 關鍵成功策略
  • 10 家主要公司的產品映射
  • 競賽儀表板
  • 比賽熱圖
  • 主要發展

第 9 章公司簡介

  • Sanofi
  • Novartis AG
  • Merck & Co.
  • Abbvie Inc
  • Pfizer Inc.
  • Accord Healthcare Limited
  • Bristol Myer Squibb
  • Asahi Kasei Corporation
  • Glaxosmithkline plc
  • Incyte Corporation
Product Code: A11929

The global Graft Versus Host Disease Market was valued at $2,968.6 million in 2021, and is projected to reach $10,375.3 million by 2031, registering a CAGR of 13.5% from 2022 to 2031.

Graft versus host disease (GVHD) is a condition that might occur after an allogeneic transplant (bone marrow transplant). In GVHD, the donated bone marrow or peripheral blood stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body. There are two forms of GVHD: acute graft versus host disease (aGVHD) and chronic graft versus host disease (cGVHD).

The pathophysiology of aGVHD and cGVHD remains incompletely understood. One commonly quoted model suggests three distinct stages in the development of aGVHD: a conditioning regimen, which damages host tissues, including intestinal mucosa and liver; activation of donor T cells against host antigens & subsequent clonal T-cell expansion; and release of inflammatory cytokines such as interleukin 1 (IL-1) & tumor necrosis factor (TNFα), leading to further host tissue damage. Several mechanisms have been implicated in cGVHD pathogenesis, including persistence of donor-derived alloreactive T cells, autoreactive T cells, B cells producing antibodies against the host, and mechanisms of chronic inflammation leading to end organ fibrosis.

Despite decades of research and improvements in post-transplant immunosuppressive therapies, graft-versus-host disease (GVHD) remains a significant cause of morbidity and mortality in allogenic hematopoietic stem-cell transplant (HSCT) recipients.

The COVID-19 pandemic has had an impact on a variety of businesses around the world. The Graft Versus Host Disease Market had a significant impact as well. To halt the spread of COVID-19, governments around the world implemented harsh restrictions such as border locks, lockdowns, and tight social distancing measures. These measures had a significant impact on the global economy, affecting a variety of industries. Pharmaceutical and biotech companies together with governments around the globe work to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline.

Impact of COVID-19: The COVID-19 pandemic has significantly changed the landscape of kidney transplantation in the U.S. and worldwide. In addition to adversely impacting allograft and patient survival in post kidney transplant recipients, the current pandemic has affected all aspects of transplant care, including transplant referrals and listing, organ donation rates, organ procurement and shipping, and waitlist mortality.

As kidney transplantation rates declined, so did organ procurement rates. The UK reported a 39% decrease in referrals of organs to OPOs. France reported a 16% decrease in all deceased organ procurement rates as compared to previous years. Part of these declines were due to procurement challenges faced by transplant programs and organizations, such as insufficient testing capabilities and delayed COVID-19 test results, limited operating room availabilities, and mandates for the avoidance of nonessential clinical activities to preserve personnel and protective equipment.

Therefore, the overall impact of COVID-19 remains negative on graft versus host disease market due to decline in number of transplantation procedure. The transplant procedure requires the routine use of reusable equipment with close contact with patients. This increases the risk of disease transmission.

Increase in number of grafts versus host disease, which arises predominantly due to rise in number of allogenic transplantations. Also, increase in disease diagnosis rate and increase in number of products available for the treatment of graft versus host disease are the factors fueling the growth of the market.

According to preliminary data from the Organ Procurement and Transplantation Network, in 2020 organ donation from deceased donors in the U.S. set an all-time record. A total of 12,587 people provided one or more organs to save and enhance the lives of others, representing an increase of six percent over 2019.

Moreover, much of the increase in deceased donation was made possible by donors representing less traditional medical criteria. The most common age range of deceased donors was 50 to 64. The 3,726 donors in this category increased by 7.9 percent over 2019. Donation increased significantly among individuals who died of cardiorespiratory failure as opposed to brain death; the 3,223 donors after cardiorespiratory death (DCD donors) increased by 18.6 percent over the total in 2019.

According to Organ Donation Statistics, 105,988 number of men, women, and children are on the national transplant waiting list, whereas 17 people die each day waiting for the organ transplant and an estimated 40,000 transplants were performed in 2021.

Complications such as allergic reactions, which cannot be detected by computational biology and other post-surgery complications, unfavorable government scenario, the high initial cost and maintenance costs of the instruments, lack of standardization, and shortage of skilled workforce are expected to be the significant restraints to market growth during the forecast period.

The graft versus host disease market is segmented on the basis of product, diagnosis, types, end use, and region. By product the market is segmented into corticosteroids, monoclonal antibodies, immunosuppressants and others. On the basis of type the segment is divided into acute and chronic. On the basis of end use the segment is divided into hospital pharmacies, retail pharmacies and online pharmacies.

Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the graft versus host disease market are AbbVie, Asahi Kasei, Bristol Myer Squibb, GlaxoSmithKline, Incyte Corporation, Medac GmbH, Merck & co., Novartis, Pfizer and Sanofi.

Key Benefits For Stakeholders

The study provides an in-depth analysis of the graft versus host disease market, and the current graft versus host disease market trends and future estimations to elucidate imminent investment pockets.

It presents a quantitative analysis of the market from 2022 to 2031 to enable stakeholders to capitalize on the prevailing market graft versus host disease market opportunity.

Extensive analysis of the market based on procedures and services assists to understand the trends in the graft versus host disease industry.

Key players and their strategies are thoroughly analyzed to understand the competitive outlook of the market.

Key Market Segments

By Product Type

  • Corticosteroids
  • Monoclonal antibodies
  • Immunosuppressants
  • Others

By Treatment Type

  • Acute GVHD
  • Chronic GVHD

By End Use

  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • United Kingdom
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Turkey
    • South Africa
    • Rest of LAMEA
  • Key Market Players
    • Sanofi
    • Novartis AG
    • Merck & Co.
    • Abbvie Inc
    • Pfizer Inc.
    • Accord Healthcare Limited
    • Bristol Myer Squibb
    • Asahi Kasei Corporation
    • Glaxosmithkline plc
    • Incyte Corporation

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Corticosteroids
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
  • 4.3 Monoclonal antibodies
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Immunosuppressants
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country
  • 4.5 Others
    • 4.5.1 Key market trends, growth factors and opportunities
    • 4.5.2 Market size and forecast, by region
    • 4.5.3 Market analysis by country

CHAPTER 5: GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Acute GVHD
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Chronic GVHD
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country

CHAPTER 6: GRAFT VERSUS HOST DISEASE MARKET, BY END USE

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospitals Pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Retail Pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Online Pharmacies
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: GRAFT VERSUS HOST DISEASE MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Product Type
    • 7.2.3 North America Market size and forecast, by Treatment Type
    • 7.2.4 North America Market size and forecast, by End Use
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Product Type
      • 7.2.5.1.2 Market size and forecast, by Treatment Type
      • 7.2.5.1.3 Market size and forecast, by End Use
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Product Type
      • 7.2.5.2.2 Market size and forecast, by Treatment Type
      • 7.2.5.2.3 Market size and forecast, by End Use
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Product Type
      • 7.2.5.3.2 Market size and forecast, by Treatment Type
      • 7.2.5.3.3 Market size and forecast, by End Use
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Product Type
    • 7.3.3 Europe Market size and forecast, by Treatment Type
    • 7.3.4 Europe Market size and forecast, by End Use
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Product Type
      • 7.3.5.1.2 Market size and forecast, by Treatment Type
      • 7.3.5.1.3 Market size and forecast, by End Use
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Product Type
      • 7.3.5.2.2 Market size and forecast, by Treatment Type
      • 7.3.5.2.3 Market size and forecast, by End Use
      • 7.3.5.3 United Kingdom
      • 7.3.5.3.1 Market size and forecast, by Product Type
      • 7.3.5.3.2 Market size and forecast, by Treatment Type
      • 7.3.5.3.3 Market size and forecast, by End Use
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Product Type
      • 7.3.5.4.2 Market size and forecast, by Treatment Type
      • 7.3.5.4.3 Market size and forecast, by End Use
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Product Type
      • 7.3.5.5.2 Market size and forecast, by Treatment Type
      • 7.3.5.5.3 Market size and forecast, by End Use
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Product Type
      • 7.3.5.6.2 Market size and forecast, by Treatment Type
      • 7.3.5.6.3 Market size and forecast, by End Use
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Product Type
    • 7.4.3 Asia-Pacific Market size and forecast, by Treatment Type
    • 7.4.4 Asia-Pacific Market size and forecast, by End Use
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Product Type
      • 7.4.5.1.2 Market size and forecast, by Treatment Type
      • 7.4.5.1.3 Market size and forecast, by End Use
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Product Type
      • 7.4.5.2.2 Market size and forecast, by Treatment Type
      • 7.4.5.2.3 Market size and forecast, by End Use
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Market size and forecast, by Product Type
      • 7.4.5.3.2 Market size and forecast, by Treatment Type
      • 7.4.5.3.3 Market size and forecast, by End Use
      • 7.4.5.4 India
      • 7.4.5.4.1 Market size and forecast, by Product Type
      • 7.4.5.4.2 Market size and forecast, by Treatment Type
      • 7.4.5.4.3 Market size and forecast, by End Use
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Product Type
      • 7.4.5.5.2 Market size and forecast, by Treatment Type
      • 7.4.5.5.3 Market size and forecast, by End Use
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Product Type
      • 7.4.5.6.2 Market size and forecast, by Treatment Type
      • 7.4.5.6.3 Market size and forecast, by End Use
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Product Type
    • 7.5.3 LAMEA Market size and forecast, by Treatment Type
    • 7.5.4 LAMEA Market size and forecast, by End Use
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Product Type
      • 7.5.5.1.2 Market size and forecast, by Treatment Type
      • 7.5.5.1.3 Market size and forecast, by End Use
      • 7.5.5.2 Turkey
      • 7.5.5.2.1 Market size and forecast, by Product Type
      • 7.5.5.2.2 Market size and forecast, by Treatment Type
      • 7.5.5.2.3 Market size and forecast, by End Use
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Product Type
      • 7.5.5.3.2 Market size and forecast, by Treatment Type
      • 7.5.5.3.3 Market size and forecast, by End Use
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Product Type
      • 7.5.5.4.2 Market size and forecast, by Treatment Type
      • 7.5.5.4.3 Market size and forecast, by End Use

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Sanofi
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Novartis AG
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Merck & Co.
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Abbvie Inc
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Pfizer Inc.
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 Accord Healthcare Limited
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Bristol Myer Squibb
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Asahi Kasei Corporation
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Glaxosmithkline plc
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Incyte Corporation
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments

LIST OF TABLES

  • TABLE 1. GLOBAL GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 2. GRAFT VERSUS HOST DISEASE MARKET REVENUE, FOR CORTICOSTEROIDS, BY REGION , 2021-2031,($MILLION)
  • TABLE 3. GRAFT VERSUS HOST DISEASE MARKET FOR CORTICOSTEROIDS BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 4. GRAFT VERSUS HOST DISEASE MARKET REVENUE, FOR MONOCLONAL ANTIBODIES, BY REGION , 2021-2031,($MILLION)
  • TABLE 5. GRAFT VERSUS HOST DISEASE MARKET FOR MONOCLONAL ANTIBODIES BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 6. GRAFT VERSUS HOST DISEASE MARKET REVENUE, FOR IMMUNOSUPPRESSANTS, BY REGION , 2021-2031,($MILLION)
  • TABLE 7. GRAFT VERSUS HOST DISEASE MARKET FOR IMMUNOSUPPRESSANTS BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 8. GRAFT VERSUS HOST DISEASE MARKET REVENUE, FOR OTHERS, BY REGION , 2021-2031,($MILLION)
  • TABLE 9. GRAFT VERSUS HOST DISEASE MARKET FOR OTHERS BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 10. GLOBAL GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 11. GRAFT VERSUS HOST DISEASE MARKET REVENUE, FOR ACUTE GVHD, BY REGION , 2021-2031,($MILLION)
  • TABLE 12. GRAFT VERSUS HOST DISEASE MARKET FOR ACUTE GVHD BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 13. GRAFT VERSUS HOST DISEASE MARKET REVENUE, FOR CHRONIC GVHD, BY REGION , 2021-2031,($MILLION)
  • TABLE 14. GRAFT VERSUS HOST DISEASE MARKET FOR CHRONIC GVHD BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 15. GLOBAL GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 16. GRAFT VERSUS HOST DISEASE MARKET REVENUE, FOR HOSPITALS PHARMACIES, BY REGION , 2021-2031,($MILLION)
  • TABLE 17. GRAFT VERSUS HOST DISEASE MARKET FOR HOSPITALS PHARMACIES BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 18. GRAFT VERSUS HOST DISEASE MARKET REVENUE, FOR RETAIL PHARMACIES, BY REGION , 2021-2031,($MILLION)
  • TABLE 19. GRAFT VERSUS HOST DISEASE MARKET FOR RETAIL PHARMACIES BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 20. GRAFT VERSUS HOST DISEASE MARKET REVENUE, FOR ONLINE PHARMACIES, BY REGION , 2021-2031,($MILLION)
  • TABLE 21. GRAFT VERSUS HOST DISEASE MARKET FOR ONLINE PHARMACIES BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 22. GRAFT VERSUS HOST DISEASE MARKET, BY REGION, 2021-2031,($MILLION)
  • TABLE 23. NORTH AMERICA GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 24. NORTH AMERICA GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 25. NORTH AMERICA GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 26. NORTH AMERICA GRAFT VERSUS HOST DISEASE MARKET, BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 27. U.S. GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 28. U.S. GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 29. U.S. GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 30. CANADA GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 31. CANADA GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 32. CANADA GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 33. MEXICO GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 34. MEXICO GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 35. MEXICO GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 36. EUROPE GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 37. EUROPE GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 38. EUROPE GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 39. EUROPE GRAFT VERSUS HOST DISEASE MARKET, BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 40. GERMANY GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 41. GERMANY GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 42. GERMANY GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 43. FRANCE GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 44. FRANCE GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 45. FRANCE GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 46. UNITED KINGDOM GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 47. UNITED KINGDOM GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 48. UNITED KINGDOM GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 49. ITALY GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 50. ITALY GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 51. ITALY GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 52. SPAIN GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 53. SPAIN GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 54. SPAIN GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 55. REST OF EUROPE GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 56. REST OF EUROPE GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 57. REST OF EUROPE GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 58. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 59. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 60. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 61. ASIA-PACIFIC GRAFT VERSUS HOST DISEASE MARKET, BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 62. JAPAN GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 63. JAPAN GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 64. JAPAN GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 65. CHINA GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 66. CHINA GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 67. CHINA GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 68. AUSTRALIA GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 69. AUSTRALIA GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 70. AUSTRALIA GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 71. INDIA GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 72. INDIA GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 73. INDIA GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 74. SOUTH KOREA GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 75. SOUTH KOREA GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 76. SOUTH KOREA GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 77. REST OF ASIA-PACIFIC GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 78. REST OF ASIA-PACIFIC GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 79. REST OF ASIA-PACIFIC GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 80. LAMEA GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 81. LAMEA GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 82. LAMEA GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 83. LAMEA GRAFT VERSUS HOST DISEASE MARKET, BY COUNTRY, 2021-2031,($MILLION)
  • TABLE 84. BRAZIL GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 85. BRAZIL GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 86. BRAZIL GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 87. TURKEY GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 88. TURKEY GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 89. TURKEY GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 90. SOUTH AFRICA GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 91. SOUTH AFRICA GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 92. SOUTH AFRICA GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 93. REST OF LAMEA GRAFT VERSUS HOST DISEASE MARKET, BY PRODUCT TYPE, 2021-2031,($MILLION)
  • TABLE 94. REST OF LAMEA GRAFT VERSUS HOST DISEASE MARKET, BY TREATMENT TYPE, 2021-2031,($MILLION)
  • TABLE 95. REST OF LAMEA GRAFT VERSUS HOST DISEASE MARKET, BY END USE, 2021-2031,($MILLION)
  • TABLE 96.SANOFI: COMPANY SNAPSHOT
  • TABLE 97.SANOFI: OPERATING SEGMENTS
  • TABLE 98.SANOFI: PRODUCT PORTFOLIO
  • TABLE 99.SANOFI: NET SALES,
  • TABLE 100.SANOFI: KEY STRATERGIES
  • TABLE 101.NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 102.NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 103.NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 104.NOVARTIS AG: NET SALES,
  • TABLE 105.NOVARTIS AG: KEY STRATERGIES
  • TABLE 106.MERCK & CO.: COMPANY SNAPSHOT
  • TABLE 107.MERCK & CO.: OPERATING SEGMENTS
  • TABLE 108.MERCK & CO.: PRODUCT PORTFOLIO
  • TABLE 109.MERCK & CO.: NET SALES,
  • TABLE 110.MERCK & CO.: KEY STRATERGIES
  • TABLE 111.ABBVIE INC: COMPANY SNAPSHOT
  • TABLE 112.ABBVIE INC: OPERATING SEGMENTS
  • TABLE 113.ABBVIE INC: PRODUCT PORTFOLIO
  • TABLE 114.ABBVIE INC: NET SALES,
  • TABLE 115.ABBVIE INC: KEY STRATERGIES
  • TABLE 116.PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 117.PFIZER INC.: OPERATING SEGMENTS
  • TABLE 118.PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 119.PFIZER INC.: NET SALES,
  • TABLE 120.PFIZER INC.: KEY STRATERGIES
  • TABLE 121.ACCORD HEALTHCARE LIMITED: COMPANY SNAPSHOT
  • TABLE 122.ACCORD HEALTHCARE LIMITED: OPERATING SEGMENTS
  • TABLE 123.ACCORD HEALTHCARE LIMITED: PRODUCT PORTFOLIO
  • TABLE 124.ACCORD HEALTHCARE LIMITED: NET SALES,
  • TABLE 125.ACCORD HEALTHCARE LIMITED: KEY STRATERGIES
  • TABLE 126.BRISTOL MYER SQUIBB: COMPANY SNAPSHOT
  • TABLE 127.BRISTOL MYER SQUIBB: OPERATING SEGMENTS
  • TABLE 128.BRISTOL MYER SQUIBB: PRODUCT PORTFOLIO
  • TABLE 129.BRISTOL MYER SQUIBB: NET SALES,
  • TABLE 130.BRISTOL MYER SQUIBB: KEY STRATERGIES
  • TABLE 131.ASAHI KASEI CORPORATION: COMPANY SNAPSHOT
  • TABLE 132.ASAHI KASEI CORPORATION: OPERATING SEGMENTS
  • TABLE 133.ASAHI KASEI CORPORATION: PRODUCT PORTFOLIO
  • TABLE 134.ASAHI KASEI CORPORATION: NET SALES,
  • TABLE 135.ASAHI KASEI CORPORATION: KEY STRATERGIES
  • TABLE 136.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
  • TABLE 137.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
  • TABLE 138.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
  • TABLE 139.GLAXOSMITHKLINE PLC: NET SALES,
  • TABLE 140.GLAXOSMITHKLINE PLC: KEY STRATERGIES
  • TABLE 141.INCYTE CORPORATION: COMPANY SNAPSHOT
  • TABLE 142.INCYTE CORPORATION: OPERATING SEGMENTS
  • TABLE 143.INCYTE CORPORATION: PRODUCT PORTFOLIO
  • TABLE 144.INCYTE CORPORATION: NET SALES,
  • TABLE 145.INCYTE CORPORATION: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.GRAFT VERSUS HOST DISEASE MARKET SEGMENTATION
  • FIGURE 2.GRAFT VERSUS HOST DISEASE MARKET,2021-2031
  • FIGURE 3.GRAFT VERSUS HOST DISEASE MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.GRAFT VERSUS HOST DISEASE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.GRAFT VERSUS HOST DISEASE MARKET,BY PRODUCT TYPE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CORTICOSTEROIDS GRAFT VERSUS HOST DISEASE MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF MONOCLONAL ANTIBODIES GRAFT VERSUS HOST DISEASE MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF IMMUNOSUPPRESSANTS GRAFT VERSUS HOST DISEASE MARKET,2021-2031(%)
  • FIGURE 16.COMPARATIVE SHARE ANALYSIS OF OTHERS GRAFT VERSUS HOST DISEASE MARKET,2021-2031(%)
  • FIGURE 17.GRAFT VERSUS HOST DISEASE MARKET,BY TREATMENT TYPE,2021(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF ACUTE GVHD GRAFT VERSUS HOST DISEASE MARKET,2021-2031(%)
  • FIGURE 19.COMPARATIVE SHARE ANALYSIS OF CHRONIC GVHD GRAFT VERSUS HOST DISEASE MARKET,2021-2031(%)
  • FIGURE 20.GRAFT VERSUS HOST DISEASE MARKET,BY END USE,2021(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF HOSPITALS PHARMACIES GRAFT VERSUS HOST DISEASE MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF RETAIL PHARMACIES GRAFT VERSUS HOST DISEASE MARKET,2021-2031(%)
  • FIGURE 23.COMPARATIVE SHARE ANALYSIS OF ONLINE PHARMACIES GRAFT VERSUS HOST DISEASE MARKET,2021-2031(%)
  • FIGURE 24.GRAFT VERSUS HOST DISEASE MARKET BY REGION,2021
  • FIGURE 25.U.S. GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 26.CANADA GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 27.MEXICO GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 28.GERMANY GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 29.FRANCE GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 30.UNITED KINGDOM GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 31.ITALY GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 32.SPAIN GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 33.REST OF EUROPE GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 34.JAPAN GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 35.CHINA GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 36.AUSTRALIA GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 37.INDIA GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 38.SOUTH KOREA GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 39.REST OF ASIA-PACIFIC GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 40.BRAZIL GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 41.TURKEY GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 42.SOUTH AFRICA GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 43.REST OF LAMEA GRAFT VERSUS HOST DISEASE MARKET,2021-2031($MILLION)
  • FIGURE 44. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 45. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 46. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 47.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 48.COMPETITIVE DASHBOARD
  • FIGURE 49.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 50.SANOFI.: NET SALES ,($MILLION)
  • FIGURE 51.NOVARTIS AG.: NET SALES ,($MILLION)
  • FIGURE 52.MERCK & CO..: NET SALES ,($MILLION)
  • FIGURE 53.ABBVIE INC.: NET SALES ,($MILLION)
  • FIGURE 54.PFIZER INC..: NET SALES ,($MILLION)
  • FIGURE 55.ACCORD HEALTHCARE LIMITED.: NET SALES ,($MILLION)
  • FIGURE 56.BRISTOL MYER SQUIBB.: NET SALES ,($MILLION)
  • FIGURE 57.ASAHI KASEI CORPORATION.: NET SALES ,($MILLION)
  • FIGURE 58.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
  • FIGURE 59.INCYTE CORPORATION.: NET SALES ,($MILLION)